BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Syensqo and Emulseo Partner to Advance Microfluidic Innovations in Healthcare

Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations f...

February 21, 2025 | News

Thermo Fisher Secures FDA Clearance for Multiplex Test Targeting Four Major Respiratory Viruses

Thermo Fisher Scientific has announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Applied Biosystems™ TaqPath&trad...

February 10, 2025 | News

DIOSynVax Introduces New Influenza Vaccine Portfolio and Advisory Board to Tackle Global Pandemic Threats

DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated ...

January 09, 2025 | News

Thermo Fisher Concludes Successful Bioprocess World Tour 2024 in APJ, Reigniting Industry Momentum Post-COVID

Thermo Fisher Scientific is proud to announce the successful conclusion of its highly anticipated Bioprocess World Tour 2024 in the Asia-Pacific and Japan ...

October 23, 2024 | News

Waters Introduces Innovative Tools to Simplify and Accelerate RNA Therapeutic Development

Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vacci...

October 11, 2024 | News

Hyundai Bioscience Partners with UC San Diego for Pioneering Long-COVID Clinical Trial of Antiviral Xafty®

Hyundai Bioscience USA announced that it has signed an MOU with the University of California San Diego (UCSD) to conduct an invest...

September 18, 2024 | News

Hyundai Bioscience Announces XAFTY®: A Breakthrough Broad-Spectrum Antiviral for COVID-19, Mpox, and Dengue

Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadel...

September 12, 2024 | News

Hyundai Bioscience Advances Xafty® as Sole Oral COVID-19 Treatment for High-Risk Patients Ineligible for Paxlovid®

"Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" "While maintaining...

August 29, 2024 | News

Pfizer and BioNTech Announce Mixed Results from Phase 3 Trial of Combination mRNA Vaccine for Influenza and COVID-19

Pfizer Inc. and BioNTech SE announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vac...

August 19, 2024 | News

Pfizer and BioNTech's Omicron JN.1 COVID-19 Vaccine Receives CHMP Recommendation

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Re...

June 28, 2024 | News

QIAGEN Launches Enhanced QIAstat-Dx Respiratory SARS-CoV-2 Panel in Malaysia

The CE-IVD marked QIAstat-Dx Respiratory SARS-CoV-2 Panel is available in Malaysia expanded to 23 pathogens, now includes Chlamydophila pneumoniae&nb...

June 04, 2024 | News

ProBioGen and ModeX Therapeutics Partner to Accelerate Development of Multi-Specific COVID-19 Antibody

ProBioGen, a leading contract development and manufacturing organization (CDMO), known for its innovative solutions in cell engineering and bioproces...

May 30, 2024 | News

Allucent Secures $25.5 Million Award for Decentralized COVID-19 Trial

Allucent, a global mid-sized clinical research organization (CRO), announced that it received a project award valued at $25.5 million...

May 16, 2024 | News

Vaxart Gets $9.27M BARDA Award for Phase 2b COVID-19 Oral Pill Study

“We are very honored to receive this BARDA award, which will support the innovative approach of our oral pill vaccine platform,” said Dr. Micha...

January 22, 2024 | News

Stay Connected